Intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II: Final report of 5-year results from a Japanese open-label phase 1/2 study.

MLA

Seo, Joo-Hyun, et al. “Intracerebroventricular Enzyme Replacement Therapy in Patients with Neuronopathic Mucopolysaccharidosis Type II: Final Report of 5-Year Results from a Japanese Open-Label Phase 1/2 Study.” Molecular Genetics & Metabolism, vol. 140, no. 4, Dec. 2023, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.ymgme.2023.107709.

APA

Seo, J.-H., Kosuga, M., Hamazaki, T., Shintaku, H., & Okuyama, T. (2023). Intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II: Final report of 5-year results from a Japanese open-label phase 1/2 study. Molecular Genetics & Metabolism, 140(4), N.PAG. https://doi.org/10.1016/j.ymgme.2023.107709

Chicago

Seo, Joo-Hyun, Motomichi Kosuga, Takashi Hamazaki, Haruo Shintaku, and Torayuki Okuyama. 2023. “Intracerebroventricular Enzyme Replacement Therapy in Patients with Neuronopathic Mucopolysaccharidosis Type II: Final Report of 5-Year Results from a Japanese Open-Label Phase 1/2 Study.” Molecular Genetics & Metabolism 140 (4): N.PAG. doi:10.1016/j.ymgme.2023.107709.